eCTD Filing Types for JO
Calyx RIM provides the following filing types for all application types associated with Jordan. This table lists the eCTD code and the applicable DTD or Schema for each Filing Type.
| Filing Type (Display) | Applicable DTD/Schema | eCTD Code | Available for Application Types |
|---|---|---|---|
| ASMF Filing | jo-1-0 | asmf | CTA, NDA |
| Biological Allergen | jo-1-0 | bla | CTA, NDA |
| Biological Bio-similar | jo-1-0 | bls | CTA, NDA |
| Biological Blood Product | jo-1-0 | blb | CTA, NDA |
| Biological Drug | jo-1-0 | bld | CTA, NDA |
| Biological Vaccine | jo-1-0 | blv | CTA, NDA |
| CEP Submission | jo-1-0 | cep | CTA, NDA |
| Extension Filing | jo-1-0 | extension | CTA, NDA |
| Generics | jo-1-0 | bgd | CTA, NDA |
| Generic Narcotics | jo-1-0 | bgn | CTA, NDA |
| Generic Vitamin Drug | jo-1-0 | bgv | CTA, NDA |
| Herbal Drug | jo-1-0 | hrd | CTA, NDA |
| MAA - Originator Drug | jo-1-0 | ord | CTA, NDA |
| MAA - Originator Vitamin Drug | jo-1-0 | orv | CTA, NDA |
| New Drug | jo-1-0 | mnd | CTA, NDA |
| New Narcotics | jo-1-0 | nnd | CTA, NDA |
| New Vitamin Drug | jo-1-0 | nvd | CTA, NDA |
| None | jo-1-0 | none | CTA, NDA |
| Notification with pricing | jo-1-0 | var-n2 | CTA, NDA |
| Notification without pricing | jo-1-0 | var-n1 | CTA, NDA |
| Originator Narcotics | jo-1-0 | orn | CTA, NDA |
| Periodic Safety Update Report | jo-1-0 | psur | CTA, NDA |
| Plasma Master File | jo-1-0 | pmf | CTA, NDA |
| PSUR single assessment procedure | jo-1-0 | psusa | CTA, NDA |
| Radiopharmaceutical Non-Radioactive Components (kits) | jo-1-0 | rnr | CTA, NDA |
| Radiopharmaceutical Ready-for-use Radioactive Product | jo-1-0 | rrp | CTA, NDA |
| Registration Department approval | jo-1-0 | var-ra | CTA, NDA |
| Renewal Filing | jo-1-0 | renewal | CTA, NDA |
| Risk Management Plan Filing | jo-1-0 | risk | CTA, NDA |
| Technical committee approval | jo-1-0 | var-tca | CTA, NDA |
| Transfer MA Filing | jo-1-0 | transfer-ma | CTA, NDA |
| USR Filing | jo-1-0 | usr | CTA, NDA |
| Value added medicine | jo-1-0 | vam | CTA, NDA |
| Veterinary drug | jo-1-0 | vtr | CTA, NDA |
| Withdrawal Filing | jo-1-0 | withdrawal | CTA, NDA |
| ASMF Filing | jo-1-1 | asmf | CTA, NDA |
| Biological Allergen | jo-1-1 | bla | CTA, NDA |
| Biological Bio-similar | jo-1-1 | bls | CTA, NDA |
| Biological Blood Product | jo-1-1 | blb | CTA, NDA |
| Biological Drug | jo-1-1 | bld | CTA, NDA |
| Biological Vaccine | jo-1-1 | blv | CTA, NDA |
| CEP Submission | jo-1-1 | cep | CTA, NDA |
| Extension Filing | jo-1-1 | extension | CTA, NDA |
| Generics | jo-1-1 | bgd | CTA, NDA |
| Generic Narcotics | jo-1-1 | bgn | CTA, NDA |
| Generic Vitamin Drug | jo-1-1 | bgv | CTA, NDA |
| Herbal Drug | jo-1-1 | hrd | CTA, NDA |
| MAA - Originator Drug | jo-1-1 | ord | CTA, NDA |
| MAA - Originator Vitamin Drug | jo-1-1 | orv | CTA, NDA |
| New Drug | jo-1-1 | mnd | CTA, NDA |
| New Narcotics | jo-1-1 | nnd | CTA, NDA |
| New Vitamin Drug | jo-1-1 | nvd | CTA, NDA |
| None | jo-1-1 | none | CTA, NDA |
| Notification with pricing | jo-1-1 | var-n2 | CTA, NDA |
| Notification without pricing | jo-1-1 | var-n1 | CTA, NDA |
| Originator Narcotics | jo-1-1 | orn | CTA, NDA |
| Periodic Safety Update Report | jo-1-1 | psur | CTA, NDA |
| Plasma Master File | jo-1-1 | pmf | CTA, NDA |
| PSUR single assessment procedure | jo-1-1 | psusa | CTA, NDA |
| Radiopharmaceutical Non-Radioactive Components (kits) | jo-1-1 | rnr | CTA, NDA |
| Radiopharmaceutical Ready-for-use Radioactive Product | jo-1-1 | rrp | CTA, NDA |
| Registration Department approval | jo-1-1 | var-ra | CTA, NDA |
| Renewal Filing | jo-1-1 | renewal | CTA, NDA |
| Risk Management Plan Filing | jo-1-1 | risk | CTA, NDA |
| Technical committee approval | jo-1-1 | var-tca | CTA, NDA |
| Transfer MA Filing | jo-1-1 | transfer-ma | CTA, NDA |
| USR Filing | jo-1-1 | usr | CTA, NDA |
| Value added medicine | jo-1-1 | vam | CTA, NDA |
| Veterinary drug | jo-1-1 | vtr | CTA, NDA |
| Withdrawal Filing | jo-1-1 | withdrawal | CTA, NDA |
| Periodic Benefit-Risk Evaluation Report | jo-1-1 | pbrer | CTA, NDA |